Pharmaceutical Companies, Distributors Accused of Contributing to Widespread Opioid Abuse

New to ClassAction.org? Read our Newswire Disclaimer

A proposed class action has been filed against a group of pharmaceutical companies and distributors over claims that they deceptively marketed and sold opioids without fully disclosing their associated risks. Among the drugs named in the suit are OxyContin and Percocet, which the complaint notes are effective for treating “short-term post-surgical and trauma-related pain,” but, when taken for prolonged periods of time, can be highly addictive and present “significant” side effects. The suit argues that despite the dangers associated with long-term use of their products, the defendants attempted to expand the market for opioids and convince medical professionals through deceptive marketing that the drugs could be safely used to treat “a wider range of problems,” including “common aches and pains.”

The complaint accuses the defendants of contributing to widespread opioid abuse across the country, which the Food and Drug Administration reportedly declared “a public health crisis” in March of 2016. The suit goes on to allege that the defendants have “failed their duty” to monitor opioid use and prevent abuse of the drugs and have instead focused on generating “massive profits” for their own benefit.

The full complaint, including a list of the more than 20 defendants, can be read below.